Generic Industry’s Drug Shortage Program Creates Trigger Mechanism For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
GPhA enlists IMS Health for analysis of production data to help FDA devise roadmap to ameliorate shortages when a company plans to halt or interrupt a drug’s manufacture.
You may also be interested in...
GPhA’s Neas Preaches Vigilance Against Reopening Hatch-Waxman Act
After five months on the job, Generic Pharmaceutical Association President and CEO Ralph Neas is optimistic about the industry’s future but prepared to do battle against any efforts to re-work the landmark 1984 law. Preparations include establishing a new non-profit arm, the Affordable Medicine Research Institute, which will focus on research and public education about generics and biosimilars.
Drug Shortages: Generic Industry’s Self Regulation Proposal Questioned At House Hearing
Mylan’s Heather Bresch still has questions and House members ask whether it could coexist with mandatory FDA reporting legislation.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.